Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx and RedHill Biopharma Announce Signing of Definitive Agreement for Commercialization of RIZAPORT(TM) with Grupo Juste for Spain and Additional Potential Territories

MarketWire Canada July 5, 2016

RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT™ for Migraines with Grupo JUSTE in Spain and Additional Potential Territories

GlobeNewswire July 5, 2016

IntelGenx Reports Amendment of Stock Option Plan

MarketWire Canada May 12, 2016

IntelGenx Reports First Quarter 2016 Financial Results

MarketWire Canada May 10, 2016

IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016

Marketwired May 5, 2016

RedHill Biopharma and IntelGenx Announce RIZAPORT(TM) Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories

GlobeNewswire March 29, 2016

IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste for Spain and Additional Potential Territories

Marketwired March 29, 2016

IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical Company for Up to Three Products

Marketwired March 24, 2016

IntelGenx Reports Record 2015 Financial Results

Marketwired March 22, 2016

IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results on Wednesday, March 23

Marketwired March 9, 2016

IntelGenx Appoints Dr. Dana Matzen as Vice President, Business Development

Marketwired March 2, 2016

RedHill Biopharma Announces Notice of Allowance for U.S. Patent Covering RIZAPORT(TM) for Migraines

GlobeNewswire February 18, 2016

IntelGenx Announces USPTO Has Granted Patent Protecting RIZAPORT(TM) Oral Film for Migraines

Marketwired February 18, 2016

IntelGenx Files Loxapine Oral Film Patent for Schizophrenia

Marketwired February 10, 2016

IntelGenx Announces Creation of a Scientific Advisory Board

Marketwired February 4, 2016

IntelGenx Appoints Mark Nawacki as Special Advisor

Marketwired January 28, 2016

IntelGenx Strengthens Senior Management Team

Marketwired January 22, 2016

IntelGenx and RedHill Biopharma Announce First European Marketing Approval of RIZAPORT(TM) for Migraines

Marketwired November 9, 2015

RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines

GlobeNewswire November 9, 2015

IntelGenx Reports Record Third Quarter 2015 Financial Results

Marketwired November 3, 2015